

CBE ID

0631

Title

Secondary Prevention of Cardiovascular Events - Use of Aspirin or Antiplatelet Therapy

Project

National Voluntary Consensus Standards For Clinically Enriched Administrative Data

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Full Year 2009

Removal Date

Mon, 02/03/2014 - 19:00

Initial Endorsement

Thu, 12/03/2009 - 19:00

Steward

ActiveHealth Management

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The percentage of adult patients, 21 years and older, with diagnosis of ischemic vascular disease (IVD) that are taking aspirin or an antiplatelet agent

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice, Clinician: Individual, Facility, Health Plan, Integrated Delivery System,

Other, Population: Community, County or City, Population: Regional and State

1.9 Care Setting

Home Care, Outpatient Services

1.14 Numerator

Patients that are taking aspirin or an antiplatelet agent in the past 6 months

1.15 Denominator

All patients, ages 21 and older, diagnosed with IVD as defined by coronary artery disease, peripheral vascular disease or cerebrovascular disease.

1.20 Types of Data Sources

Claims Data, Electronic Health Data, Electronic Health Records: Electronic Health Records, Instrument-Based Data

6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

6.1.3 Current Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

Exclusions

Patients with contraindications to antithrombotic agents such as thrombocytopenia, coagulopathy, recent procedures, or current warfarin therapy

General exclusions:

- Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
- Patients who have been in a skilled nursing facility in the last 3 months
- Patient or provider feedback indicating allergy or intolerance to the drug in the past
- Patient or provider feedback indicating that there is a contraindication to adding the drug

Planned Use

Public Reporting, Quality Improvement (Internal to the specific organization)

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

ActiveHealth Management

Steward POC email

mvemireddy@activehealth.net